Can the Development and Recurrence of Uveitis in Behçet’s Disease be Predicted? Which Predictors Are at the Forefront?

Abstract

ABSTRACT Objective One of the main manifestations of Behçet's disease (BD) with the highest morbidity rate is uveitis. Uveitis recurrence (UR) rate is still high and can cause significant physical and mental distress in patients with BD, and prolonged treatment is also a major financial burden. We aimed to determine the factors predicting the development and recurrence of uveitis and to calculate the time to development and recurrence of uveitis. Material and Methods In a two-center retrospective study, a total of 78 BD patients who met the international criteria for Behçet’s disease (ICBD), 41 patients with uveitis and 37 patients without uveitis, were included. Results The absence of genital ulcer (GU) alone was found to be an independent factor with 65.3% probability of the development of uveitis (DoU). The rate of predicting DoU was 72.2% when the prolonged time to diagnosis and the absence of GA were combined. In patients with a body mass index (BMI) of 25 kg/m2, the risk of UR was 70%. Conclusion Two main findings of this study were that uveitis and UR were more common in patients without GU and with high BMI, respectively.

Keywords

• Behçet’s disease
• body mass index
• genital aphthae
• uveitis.

Behçet Hastalığında Üveit Gelişimi ve Rekürrensi Öngörülebilir mi? Ön Planda Hangi Öngörücüler Yer Almaktadır?

Öz

ÖZ Amaç Üveit, Behçet hastalığının (BH) en yüksek morbidite oranına sahip olan ana manifestasyonlarından biridir. BH'da üveit rekürrens (UR) oranı hâlâ yüksektir ve bu hastalarda fazlaca fiziksel ve ruhsal strese neden olabilir, uzun süreli tedavi de aynı zamanda büyük bir mali yük getirmektedir. Bu çalışmada üveit gelişimi ve rekürrensini öngören faktörleri belirlemeyi ve üveit gelişimi ve rekürrensine kadar geçen süreyi hesaplamayı amaçladık. Gereç ve Yöntemler İki merkezli retrospektif çalışmada, Behçet hastalığı için uluslararası kriterleri (ICBD) karşılayan 41 üveiti olan ve 37 üveiti olmayan toplam 78 BH hastası çalışmaya dahil edildi. Bulgular Sadece genital ülser (GU) olmaması, üveit gelişimi (DoU) için %65,3 olasılıkla bağımsız bir faktör olarak bulundu. Tanıya kadar geçen uzun süre ve GA'nın yokluğu kombine edildiğinde DoU'yu öngörme oranı %72,2 idi. Vücut kitle indeksi (VKİ) 25 kg/m2 olan hastalarda UR riskinin %70 olduğu belirlendi. Sonuç Çalışmamızın iki ana bulgusu, GU olmayan ve yüksek VKİ'si olan hastalarda üveit ve UR'nin daha yaygın olmasıdır.

Anahtar Kelimeler

• Behçet hastalığı
• genital aft
• üveit
• vücut kitle indeksi

Kaynakça

1. 1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL,Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CGM, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DGI, Specks U, Stone JH, Takahashi K, Watts RA. 2012 Revised InternationalChapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis & Rheumatism2012; 65(1):1-11.
2. 2. Behcet H. Uber rezidiverende aphthose durch ein virus verursachte Geschwure am Mund,am Auge, und n den Genitalien. Dermatol Wochenschr 1937; 105:1152–7.
3. 3. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet’s Disease. New England Journal of Medicine 1999; 1(17):1284-91.
4. 4. Hairallah M, Accorinti M, Muccioli C, Kahloun R, Kempen JH. Epidemiology of Behçet Disease. Ocular ımmunology and Inflammation 2012; 20(5):324-35.
5. 5. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Altunbas H, Urgancioglu M. Uveitis in Behçet disease: An analysis of 880 patients. American Journal of Ophthalmology 2004; 138(3):373-80.
6. 6. Wakefield D, Cunningham ET, Tugal-Tutkun I, Khairallah M, Ohno S, Zierhut M. Controversies in Behçet Disease. Ocular Immunology and Inflammation 2012; 20(1):6-11.
7. 7. Yang P, Fang W, Meng Q, Ren Y, Xing L, Aize Kijlstra. Clinical Features of Chinese Patients with Behçet’s Disease. Ophthalmology 2008; 115(2):312-18.e4.
8. 8. Amer R, Alsughayyar W, Almeida D. Pattern and causes of visual loss in Behçet’s uveitis: short-term and long-term outcomes. Graefe’s Archive for Clinical and Experimental Ophthalmology 2017; 255(7):1423-32.

9. 9. Desbois AC, Terrada C, Cacoub P, Bodaghi B, Saadoun D. Les manifestations oculaires de la maladie de Behçet. La Revue de Médecine Interne 2018; 39(9):738-45.
10. 10. Zhong Z, Su G, Yang P. Risk factors, clinical features and treatment of Behçet’s disease uveitis. Progress in Retinal and Eye Research. 2023;97:101216.
11. 11. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. American Journal of Ophthalmology 2005;140(3):509-16.
12. 12. Nair JR, Moots RJ. Behcet’s disease. Clinical Medicine 2017; 17(1):71-7.
13. 13. Davatchi F, Assaad-Khalil S, Calamia KT, Crook JE, Sadeghi-Abdollahi B, Schirmer M, Tzellos T, Zouboulis CC, Akhlagi M, Al-Dalaan A, Alekberova ZS, Ali AA, Altenburg A, Arromdee E, Baltaci M, Bastos M, Benamour S, Ben Ghorbel I, Boyvat A, Carvalho L, Chen W, Ben-Chetrit E, Chams-Davatchi C, Correia JA, Crespo J, Dias C, Dong Y, Paixão-DuarteF, Elmuntaser K, Elonakov AV, Gil Graña J, Haghdoost AA, Hayani RM, Houman H, Isayeva AR, Jamshidi AR, Kaklamanis P, Kumar A, Kyrgidis A, Madanat W, Nadji A, Namba K, Ohno S, Olivieri I, Patto Vaz J, Pipitone N, de Queiroz MV, Ramos F, Resende C, Rosa CM, Salvarani C, Serra MJ, Shahram F, Shams H, Sharquie KE, Sliti-Khanfir M, de Abreu TriboletT, Vasconcelos C, Vedes J, Wechsler B, Cheng YK, Zhang Z, Ziaei N. The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivityand specificity of the new criteria. Journal of the European Academy of Dermatology and Venereology 2013; 28(3):338-47.
14. 14. JH Cheon, ES Kim, SJ Shin, TI Kim, KM Lee, SW Kim, JS Kim, YS Kim, CH Choi, BDYe, SK Yang, EH Choi, WH Kim. Development and Validation of Novel Diagnostic Criteria for Intestinal Behçet’s Disease in Korean Patients With Ileocolonic Ulcers. The American Journal of Gastroenterology 2009; 104(10):2492-99.
15. 15. Watanabe K, Tanida S, Inoue N, Kunisaki R, Kobayashi K, Nagahori M, Arai K, Uchino M, Koganei K, Kobayashi T, Takeno M, Ueno F, Matsumoto T, Mizuki N, Suzuki Y, Hisamatsu T. Evidence-based diagnosis and clinical practice guidelines for intestinal Behçet’s disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants. Journal of Gastroenterology 2020; 55(7):679-700.
16. 16. Lawton G, Bhakta BB, Chamberlain MA, Tennant A. The Behçet’s disease activity index. Rheumatology (Oxford) 2004; 43:73–8.
17. 17. Tabachnick BG, Fidell LS. Using Multivariate Statistics. 6th ed. Boston Pearson; 2013.
18. 18. Tuğal-Tutkun İ. Uveitis in Behçet dis- ease-an update. Curr Opin Rheumatol 2023; 35(1):17-24.
19. 19. Yazici H, Tuzun Y, Pazarli H, Yurdakul S, Ozyazgan Y, Ozdogan H, Serdaroglu S, Ersanli M, Ulku BY, Mutlugil A, Tunckale F. Influence of age of onset and patient’s sex on the prevalence and severity of manifestations of Behcet’s syndrome. Annals of the Rheumatic Diseases 1984; 43(6):783-9.
20. 20. Torğutalp M, Şahin Eroğlu D, Sezer S, Yayla ME, Karataş G, Özel EM, Dinçer Abk, Yüksel ML, Gülöksüz E, Yılmaz R, Turgay TM, Kınıklı G, Ateş A. Patient characteristics in Behçet’s Syndrome and their associations with major organ involvement: a single-centre experience of 2118 cases. Scandinavian Journal of Rheumatology. 2021;51(1):50-58.
21. 21. Sota J, Donato Rigante, Emmi G, Lopalco G, Orlando I, Tosi GM, Frediani B, Vitale A, Guerriero S, Iannone F, Vannozzi L, Fabiani C, Cantarini L. Behçet’s syndrome in Italy: a detailed retrospective analysis of 396 cases seen in 3 tertiary referral clinics. Internal and Emergency Medicine 2020; 15(6):1031-9.
22. 22. Verity DH, Wallace GR, Vaughan RW, Kondeatis E, Madanat W, Zureikat H, Fayyad F, Marr JE, Kanawati CA, Stanford MR. HLA and tumour necrosis factor (TNF) polymorphisms in ocular Behçet’s disease. Tissue Antigens 1999; 54(3):264-72.
23. 23. Soejima Y, Kirino Y, Takeno M, Kurosawa M, Takeuchi M, Yoshimi R, Sugiyama Y, Ohno S, Asami Y, Sekiguchi A, Igarashi T, Nagaoka S, Ishigatsubo Y, Nakajima H, Mizuki N. Changes in the proportion of clinical clusters contribute to the phenotypic evolution of Behçet’s disease in Japan. Arthritis Research & Therapy 2021; 23(1):49.
24. 24. Zhong Z, Su G, Zhou Q, Meguro A, Takeuchi M, Mizuki N, Ohno S, Liao W, Feng X, Ding J, Gao Y, Chi W, Zhang M, Zuo X, Yang P. Tuberculosis Exposure With Risk of Behçet Disease Among Patients With Uveitis. JAMA Ophthalmology 2021; 139(4):415-422.
25. 25. Seyahi E. Phenotypes in Behçet’s syndrome. Internal and Emergency Medicine 2019; 14(5):677-89.
26. 26. Soejima Y, Kirino Y, Takeno M, Kurosawa M, Takeuchi M, Yoshimi R, Sugiyama Y, Ohno S, Asami Y, Sekiguchi A, Igarashi T, Nagaoka S, Ishigatsubo Y, Nakajima H, Mizuki N. Changes in the proportion of clinical clusters contribute to the phenotypic evolution of Behçet’s disease in Japan. Arthritis Research & Therapy 2021; 23(1) :49.
27. 27. Zou J, Luo J, Yan S, Cai J, Guan JL. Cluster analysis of phenotypes of patients with Behçet’s syndrome: a large cohort study from a referral center in China. Arthritis Research & Therapy. 2021;23(1).
28. 28. Attia DHS. Behçet’s disease phenotypes and clinical outcomes: A cohort study in egyptian patients. Reumatología Clínica 2021; 17(9):514-20.
29. 29. Dick AD, Dunn JP, Kramer M, McCluskey P, Oden N, Okada AA, Palestine AG, Read RW, Thorne JE, Trusko BE, Steven Y. Classification Criteria for Behçet Disease Uveitis. American Journal of Ophthalmology 2021; 228:80-88.
30. 30. Cai J, Qi L, Chen Y , Zou J, Shen Y, Luo D, Bao H, Ye J, Ma H, Guan JL. Evaluation of factors for predicting risk of uveitis recurrence in Behcet’s disease patients. Braz J Med Biol Res 2020; 53(6):e9118.
31. 31. Coelho M, Oliveira T, Fernandes R. Biochemistry of adipose tissue: an endocrine organ. Arch Med Sci. 2013;9(2):191-200.
32. 32. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. The New England journal of medicine 1996; 334(5):292-5.
33. 33. Saladin R, De Vos P, Guerre-Millo M, et al. Transient increase in obese gene expression after food intake or insulin administration. Nature 1995; 377(6549):527-9.
34. 34. Hamilton BS, Paglia D, Kwan AY, Deitel M. Increased obese mRNA expression in omental fat cells from massively obese humans. Nature Medicine 1995; 1(9):953-6.
35. 35. Kavuncu S, Koç F, Kurt M, Eryüksel B, Ortaç S, Ozdal P, Firat E. Evaluation of serum leptin concentration in Behçet’s disease with ocular involvement. Graefes Archive for Clinical and Experimental Ophthalmology 2005; 243(11):1158-60.
36. 36. Yalçındağ FN, Kısa Ü, Batıoğlu F, Yalçındağ A, Özdemir Ö, Çağlayan O. Serum Leptin Levels in Patients with Ocular and Nonocular Behçet’s Disease. Mediators of Inflammation 2007; 2007: 31986.